Academic publishing company Wiley (NYSE: WLY) and IQVIA (NYSE: IQV), a provider of provider of clinical research service, announced on Monday the release of a joint report, Scientific Discovery & AI: The Science-to-Patient Journey, examining the opportunities and constraints of artificial intelligence across the healthcare value chain.

The report draws on insights from an invitation-only summit held in May 2026, co-hosted by Wiley and IQVIA, which brought together more than 25 senior leaders from pharma, academia, health systems, technology firms and publishing. Contributors included organisations such as Novo Nordisk, Microsoft, Amazon, Salesforce, AAAS, JAMA Network and Johns Hopkins University.

A central theme of the findings is the gap between AI capability and the healthcare system's ability to integrate it effectively. While AI is accelerating progress from discovery to patient care, the report notes that gains at one stage of development can create bottlenecks elsewhere in the system.

The report identifies five key areas of opportunity: decision-first discovery to support target identification, structured sharing of negative research data, patient-facing AI agents, improved aggregation of scientific and real-world data, and continuous feedback loops between clinical outcomes and research design.

It also highlights structural challenges, particularly misaligned incentives across the healthcare ecosystem, which may limit the translation of AI advances into patient outcomes without coordinated reform.

Wiley and IQVIA said the report reflects their combined position across the full scientific and clinical value chain, from research publication through to real-world healthcare data and evidence generation.